Last reviewed · How we verify
CAR-NK-CD19 Cells
At a glance
| Generic name | CAR-NK-CD19 Cells |
|---|---|
| Sponsor | Shanghai Simnova Biotechnology Co.,Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2) (PHASE1, PHASE2)
- Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refractory Pediatric Rheumatic Diseases (EARLY_PHASE1)
- A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Kinetics of Universal Car-t Cell Injection in CD19 and / or CD20 Positive Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia in Adolescents, Children and Adults (EARLY_PHASE1)
- A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) (PHASE1, PHASE2)
- Exploratory Clinical Study of Second-generation CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in Treating Paediatric B Cell-related Autoimmune Diseases (EARLY_PHASE1)
- KN5501 Cell Injection for Refractory SLE(CLEAR) (PHASE1)
- A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases (PHASE1)
- Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |